NEXT SCIENCE LIMITED (NXS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NXS - NEXT SCIENCE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.265

22 Jul
2024

-0.025

OPEN

$0.29

-8.62%

HIGH

$0.31

219,446

LOW

$0.24

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-10.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.4 M
Book Value Per Share xxxxxxxxxxxxxxx6.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-22.7 M
Net Profit Margin xxxxxxxxxxxxxxx-73.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-160.01 %
Return on Invested Capital xxxxxxxxxxxxxxx-148.27 %
Return on Assets xxxxxxxxxxxxxxx-109.91 %
Return on Equity xxxxxxxxxxxxxxx-160.01 %
Return on Total Capital xxxxxxxxxxxxxxx-142.67 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-23.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx14 M
Price To Book Value xxxxxxxxxxxxxxx5.28

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx3.99 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx47 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

08/03/2024

3

Market Weight

$0.34

28.30%

Next Science delivered revenue in 2023 that was ahead of estimates. Wilsons was pleased with the growth in DME sales in the fourth quarter, with this being the first full year's contribution from that business.

This coincided with expanded GPO access for Xperience with revenue up 48% after a long period of weakness. The broker now finds the path to profitability much easier to envisage yet, as a funding gap needs to be addressed, a Market Weight rating is retained. Target is raised to $0.34 from $0.33.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -4.27 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.20 cents.
Access Stockbroker Research History >

NXS STOCK CHART

FNArena News on NXS

1
Australian Broker Call *Extra* Edition – May 07, 2024

May 07 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 08, 2024

Mar 08 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 09, 2024

Feb 09 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 06, 2024

Feb 06 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

10:30 AM - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps